CHKα

CHKα (choline kinase alpha, CHKA) catalyzes the ATP-dependent phosphorylation of choline to phosphocholine, the first committed step of the CDP-choline pathway that drives phosphatidylcholine biosynthesis and membrane phospholipid production^[1][2]. CHKα functions as a central regulator of choline metabolism and supports the generation of phospholipid intermediates required for cellular growth, proliferation, and membrane remodeling^[1][3]. Mechanistically, CHKA encodes two alternatively spliced isoforms, CHKα1 and CHKα2, whereas the related CHKB gene encodes CHKβ, establishing distinct choline kinase isoforms with different biochemical and biological functions^[2]. Compared with CHKβ, CHKα is the predominant mammalian isoform and is more strongly associated with phosphocholine accumulation and phosphatidylcholine biosynthesis in proliferating cells^[2][4]. In disease settings, CHKα overexpression and hyperactivation are frequently observed in multiple human malignancies, including hepatocellular carcinoma, ovarian cancer, prostate cancer, colorectal cancer, and other solid tumors, where elevated phosphocholine metabolism correlates with tumor progression and aggressive cellular phenotypes^[3][5][6]. Experimental studies further demonstrate that CHKα contributes to oncogenic signaling networks, including interactions with growth factor and mTOR-associated pathways that support tumor cell proliferation and survival^[3][5]. Therefore, selective CHKα inhibition has emerged as a research strategy for suppressing aberrant choline metabolism, and multiple small-molecule CHKα inhibitors have been developed as pharmacological tools for cancer biology and therapeutic investigation^[3][7].